$1 Billion is the total value of Vivo Capital, LLC's 49 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 17.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | Ascendis Pharma A/Sadr | $240,912,000 | +77.5% | 2,046,832 | -5.5% | 24.02% | +38.6% |
| CRNX | Sell | Crinetics Pharmaceuticals Inc | $76,819,000 | -32.5% | 3,375,169 | -11.0% | 7.66% | -47.3% |
| CDXS | Sell | Codexis, Inc | $53,767,000 | +18.6% | 2,618,951 | -3.5% | 5.36% | -7.4% |
| ARWR | Arrowhead Pharmaceuticals Inc | $42,728,000 | +47.7% | 2,328,475 | 0.0% | 4.26% | +15.4% | |
| KALV | KalVista Pharmaceuticals Inc. | $38,899,000 | +44.9% | 1,359,149 | 0.0% | 3.88% | +13.2% | |
| SVA | Sinovac Biotech Ltd. | $38,173,000 | -6.8% | 5,900,000 | 0.0% | 3.81% | -27.2% | |
| INSM | New | Insmed Inc | $34,020,000 | – | 1,170,290 | +100.0% | 3.39% | – |
| KDMN | Buy | Kadmon Holdings Inc | $33,281,000 | +53.1% | 12,606,605 | +20.6% | 3.32% | +19.5% |
| FIXX | Homology Medicines, Inc. | $32,160,000 | +24.0% | 1,159,742 | 0.0% | 3.21% | -3.2% | |
| MNLO | Menlo Therapeutics Inc. | $31,488,000 | +90.5% | 4,011,236 | 0.0% | 3.14% | +48.8% | |
| TCDA | Tricida, Inc. | $29,529,000 | +60.4% | 781,185 | 0.0% | 2.94% | +25.2% | |
| CBAY | Buy | Cymabay Therapeutics Inc | $27,304,000 | +282.9% | 2,056,000 | +126.9% | 2.72% | +198.9% |
| BHVN | Sell | Biohaven Pharmaceutical Holding Company Ltd | $25,991,000 | -61.2% | 504,980 | -72.2% | 2.59% | -69.7% |
| EIGR | Eiger BioPharmaceuticals Inc | $25,042,000 | +37.6% | 1,791,257 | 0.0% | 2.50% | +7.4% | |
| MRTX | Mirati Therapeutics Inc. | $18,406,000 | +72.8% | 251,107 | 0.0% | 1.84% | +34.9% | |
| MEIP | MEI Pharma Inc | $17,739,000 | +16.3% | 5,778,106 | 0.0% | 1.77% | -9.2% | |
| KNSA | Buy | Kiniksa Pharmaceuticals | $15,233,000 | +104.7% | 843,478 | +218.4% | 1.52% | +59.9% |
| IOVA | Iovance Biotherapeutics, Inc. | $15,216,000 | +7.5% | 1,600,000 | 0.0% | 1.52% | -16.1% | |
| XENE | Xenon Pharmaceuticals Inc | $14,280,000 | +61.0% | 1,405,476 | 0.0% | 1.42% | +25.7% | |
| ACER | Acer Therapeutics Inc | $14,071,000 | +20.8% | 579,051 | 0.0% | 1.40% | -5.7% | |
| OBSV | Obseva SA | $11,986,000 | +1.0% | 937,147 | 0.0% | 1.20% | -21.1% | |
| AMRS | Amyris, Inc | $11,653,000 | -37.4% | 5,575,785 | 0.0% | 1.16% | -51.1% | |
| QURE | New | Uniqure NV | $10,757,000 | – | 180,336 | +100.0% | 1.07% | – |
| Sell | Nabriva Therapeutics AG | $10,745,000 | +11.2% | 4,403,687 | -33.5% | 1.07% | -13.2% | |
| ZYME | Zymeworks Inc | $10,034,000 | +10.2% | 620,134 | 0.0% | 1.00% | -13.9% | |
| ACRS | Aclaris Therapeutics, Inc. | $9,867,000 | -18.9% | 1,647,214 | 0.0% | 0.98% | -36.7% | |
| VRNA | Verona Pharma PLCads | $9,704,000 | -27.8% | 1,492,951 | 0.0% | 0.97% | -43.6% | |
| DERM | New | Dermira Inc | $9,485,000 | – | 700,000 | +100.0% | 0.95% | – |
| SLNO | Soleno Therapeutics, Inc. | $8,981,000 | +20.5% | 4,359,683 | 0.0% | 0.90% | -5.9% | |
| KALA | Kala Pharmaceuticals, Inc. | $8,626,000 | +69.1% | 1,043,020 | 0.0% | 0.86% | +32.1% | |
| ORTX | Sell | Orchard Therapeutics plcads | $8,611,000 | -32.6% | 481,609 | -40.7% | 0.86% | -47.3% |
| GLMD | Galmed Pharmaceuticals Ltd | $7,936,000 | +19.6% | 971,337 | 0.0% | 0.79% | -6.6% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $7,886,000 | -4.7% | 1,213,290 | 0.0% | 0.79% | -25.6% | |
| APLS | Sell | Apellis Pharmaceuticals, Inc. | $7,479,000 | -35.2% | 383,538 | -56.1% | 0.75% | -49.4% |
| MTNB | New | Matinas Biopharma Hldgs Inc | $7,432,000 | – | 6,818,181 | +100.0% | 0.74% | – |
| ZGNX | Zogenix Inc | $5,776,000 | +50.9% | 105,000 | 0.0% | 0.58% | +17.8% | |
| DTIL | New | Precision Biosciences Inc | $5,035,000 | – | 280,511 | +100.0% | 0.50% | – |
| GNCA | Sell | Genocea Biosciences Inc | $4,609,000 | +96.5% | 7,811,206 | -4.5% | 0.46% | +53.3% |
| SBBP | New | Strongbridge Biopharma plc | $4,552,000 | – | 914,062 | +100.0% | 0.45% | – |
| SRRA | Sierra Oncology, Inc | $4,169,000 | +29.5% | 2,438,270 | 0.0% | 0.42% | +1.2% | |
| AGRX | Agile Therapeutics, Inc. | $2,286,000 | +162.2% | 1,513,975 | 0.0% | 0.23% | +105.4% | |
| ZLAB | Sell | Zai Lab Limitedadr | $2,113,000 | +11.2% | 71,595 | -12.5% | 0.21% | -13.2% |
| DBVT | DBV Technologies S.A.adr | $2,082,000 | +20.1% | 269,995 | 0.0% | 0.21% | -5.9% | |
| TRVN | Sell | Trevena, Inc. | $1,925,000 | +159.1% | 1,233,677 | -28.6% | 0.19% | +102.1% |
| BPMX | BioPharmX Corporation | $1,419,000 | -18.4% | 16,128,515 | 0.0% | 0.14% | -36.5% | |
| SELB | Selecta Biosciences Inc | $1,289,000 | -11.3% | 546,054 | 0.0% | 0.13% | -30.6% | |
| AKTX | Akari Therapeutics Plcadr | $1,238,000 | +128.0% | 345,850 | 0.0% | 0.12% | +78.3% | |
| SNSS | Sell | Sunesis Pharmaceuticals, Inc. | $121,000 | +49.4% | 99,441 | -49.1% | 0.01% | +20.0% |
| SLNOW | Soleno Therapeutics, Inc. - Warrantwarrant | $28,000 | +47.4% | 188,772 | 0.0% | 0.00% | +50.0% | |
| FOMX | Exit | Foamix Pharmaceuticals Ltd. | $0 | – | -201,478 | -100.0% | -0.09% | – |
| ARVN | Exit | Arvinas Holding Co LLC | $0 | – | -209,666 | -100.0% | -0.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.